The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
MT-II · Melanotan II
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
Use the route notes below to match form, goal, and evidence quality.
No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
Melanotan II is a compound that genuinely works for tanning, genuinely produces erections and sexual arousal, and genuinely raises questions about melanoma that the evidence has not resolved. It is not a fringe compound with no activity — it has Phase I human data, a coherent receptor mechanism, and a pharmacological lineage that produced an FDA-approved drug. It is also one of the most seriously safety-flagged compounds in this reference.
The compound's story resolves here: the University of Arizona team was right that MC1R activation produces tanning. They were also right that non-selective activation of MC3R and MC4R is unavoidable with MT-II. The molecule that was designed to make tanning safer may introduce its own skin cancer risk pathway through MC1R-driven melanocyte proliferation — or it may not, because the evidence is confounded by UV-seeking behavior in the same user population. The melanoma question will not be resolved without a prospective controlled study that has not been done and likely will not be done. In this uncertainty, the practical rule is straightforward: anyone with elevated melanoma risk should not use this compound; anyone who uses it needs active dermatological surveillance.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
FDA-Approved. EMA-Approved. The First Effective Treatment for a Disease That Traps Patients Indoors. The Compound That Tans Without UV. The Nevi Darkening Warning the Community Ignores. The Melanoma Question That Has No Clean Answer. The Widest Gap in this reference Between the Disease It Was Made For and the Use It Is Actually Known For.
The Compound Designed for Patients Whose Brains Literally Cannot Signal 'Stop Eating.' The POMC/LEPR/PCSK1 Pathway Explained: Why These Patients Gain Weight from the Day They Are Born. 80% Achieved ≥10% Weight Loss in the POMC Trial. 51 kg Lost in a Single Patient in Phase II. The Off-Label Question: Does It Work When the Pathway Is Intact? Why 78% of Patients Develop Skin Hyperpigmentation — and Why That Is Not the Same Risk as Melanotan II. vs MT-II: Same Receptor Family, Opposite Selectivity Approach.
Amino-acid-derived quaternary ammonium compound involved in mitochondrial fatty-acid transport. Commercial claims are often overstated, but specific forms have clinical evidence for neuropathy, peripheral artery disease, muscle recovery, male infertility, and post-MI cardiac outcomes.